7 March 2018 - Deborah Wilkes
Archived
The US Food and Drug Administration (FDA) has authorised 23andMe's direct-to-consumer (DTC) genetic test for the risk of breast, ovarian and prostate cancer.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.